# A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

> **NCT02611310** · — · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT02611310
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-19
- **Primary completion:** 2018-11-12
- **Final completion:** 2018-11-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Recruitment Target not met
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611310, "A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02611310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*